Although the single-arm design and small sample size of the current study limit the ability to attribute clinical efficacy to the PTCV definitively, the observed response rate (30.6%) is higher than that in historical clinical trials of anti-PD-1 monotherapy in HCC (12–18%)4–10. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.